28 April 2020 - Deborah Wilkes
Archived
Sanofi Consumer Healthcare’s development plans for switching Cialis (tadalafil) and Tamiflu (oseltamivir) from prescription-to-OTC status in the US remain “on track”, according to Paul Hudson, Sanofi’s chief executive officer.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.